Core Laboratories N.v. (CLB) Tops Q2 EPS by 1c; Guides Q3
Core Laboratories N.v. (NYSE: CLB) reported Q2 EPS of $1.16, $0.01 better than the analyst estimate of $1.15. Revenue for the quarter came in at $247 million versus the consensus estimate of $251.08 million.
Core Laboratories N.v. sees Q3 2012 EPS of $1.17-$1.25, versus the consensus of $1.24. Core Laboratories N.v. sees Q3 2012 revenue of $250-$260 million, versus the consensus of $263.7 million.
For earnings history and earnings-related data on Core Laboratories N.v. (CLB) click here.
Core Laboratories N.v. sees Q3 2012 EPS of $1.17-$1.25, versus the consensus of $1.24. Core Laboratories N.v. sees Q3 2012 revenue of $250-$260 million, versus the consensus of $263.7 million.
For earnings history and earnings-related data on Core Laboratories N.v. (CLB) click here.